Richard Glickman Aurinia Pharmaceuticals CEO Rating

Aurinia Pharmaceuticals CEO Richard Glickman Bio

Dr. Richard M. Glickman, L.L.D. (Hon), serves as a Partner at Lumira Capital Corp. Dr. Glickman serves as a Venture Partner at Kearny Venture Partners. Dr. Glickman founded Aurinia Pharmaceuticals Inc. and serves as its Chief Executive Officer since February 6, 2017. Dr. Glickman served as an Acting Chief Executive Officer of Aurinia Pharmaceuticals Inc. from October 22, 2013 to November 5, 2013. Dr. Glickman served as a Business Advisor of Valocor Therapeutics, Inc. He served as a Special Advisor of MedGenesis Therapeutix Inc. He co-founded Aspreva International Ltd. in 2001 and served as its Chairman and Chief Executive Officer from January 2002 to July 11, 2007. He co-founded StressGen Biotechnologies Corporation and served as its President and Chief Executive Officer until 2000. He co-founded Probtec Corporation and served as its Vice-President of Corporate Development, where Dr. Glickman established and introduced the first licensed DNA-based forensic and paternity testing services into Canada. He founded Ontario Molecular Diagnostics. Dr. Glickman has over 30 years of experience in the creation and operation of healthcare ventures, founding and co-founding numerous companies during his career. He is the Chairman of Isotechnika Pharma Inc. since September 23, 2013 and ESSA Pharma Inc. since October 2010. He serves as a Director at ESSA Pharma Inc. since October 2010. He serves as the Chairman of Vigil Health Management and Life Sciences B.C. He has been the Chairman of the Board at Aurinia Pharmaceuticals Inc. since August 2013. He serves as the Chairman of the Board of Engene Inc. He serves as a Vice-Chairman of StressGen. He served as its Executive Chairman from September 20, 2013 to February 28, 2014. He has been a Director at Cardiome Pharma Corp. since December 11, 2006 and its Lead Independent Director since June 11, 2007. He is a Director of Isotechnika Pharma Inc. since August 15, 2013. He serves as a Director of British Columbia Innovation Council. He is a member of the Canadian federal government's National Biotechnology Advisory Committee. Dr. Glickman is an Executive of the Board of Directors of the Canadian Genetic Diseases Network. Dr. Glickman serves as a Director of Epic Biosonics Incorporated. He is a Member of Strategic Advisory Board at Ico Therapeutics Inc. since November 2005. He is a Non-Executive Director of enGene, Inc. since October 2011. He served as the Chairman of Vigil Health Solutions Inc., from 2000 to 2005. He served as a Director of MedGenesis Therapeutix Inc. He served as a Director of Vigil Health Solutions Inc. since April 7, 2000. He served as a Vice Chairman of Nventa Biopharmaceuticals Corporation. He served as a Director of Aspreva Pharmaceuticals Corporation from January 2002 to July 11, 2007 and served as Director at Kinexus Bioinformatics Corporation and Ontario Molecular Diagnostics. He served as Director of viDA Therapeutics Inc until June 23, 2016. Dr. Glickman has served on numerous biotechnology and community boards including roles as Chairman of Life Sciences B.C., Director of the Canadian Genetic Disease Network and as a Director for the Vancouver Aquarium. He is the recipient of both Canada's and British Columbia's Top 40 under 40 Awards. He received the Ernst & Young Entrepreneur of the Year 2004 Award for the Pacific Region Life Sciences Group. He has a successful track record raising capital for pharmaceutical and biopharmaceutical companies. He is one of Canada's best known and most successful healthcare entrepreneurs. Dr. Glickman holds a B.Sc. in Microbiology and Immunology from the McGill University.

Aurinia Pharmaceuticals CEO Richard Glickman At a Glance

The CEO score provides an understanding of how employees feel about the CEO’s leadership style and effectiveness at Aurinia Pharmaceuticals.

Overall, the CEO score has remained stable over the last 90 days.